Breaking the barrier: MMP2/HAase dual-triggered liposomal nanoplatform for enhanced tumor penetration and immunogenic cell death
International Immunopharmacology · 2026-12 · 191 · 117601
DOI: 10.1016/j.intimp.2026.117601 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-12. Verfasst von Liang Kong und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, 116600, China; Shenyang Key Laboratory of Chinese Medicine targeted…. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
Lung cancer is an invasive tumor prone to metastasis with poor treatment outcomes. Traditional chemotherapy fails largely due to poor tumor enrichment, low sensitivity to tumor microenvironment and severe whole-body toxicity. Herein, we built a dual-enzyme responsive Trojan horse liposome (B/T-PTX-Lip) to co-deliver paclitaxel (PTX) and PD-1/PD-L1 inhibitor BMS-1 for precise lung cancer therapy. Prepared by thin-film hydration, the liposome was modified with MMP2-cleavable peptide and hyaluronic acid to achieve active tumor targeting and microenvironment-triggered drug release. Characterizations confirmed its uniform size, good dispersion, high drug loading and stable storage. Dual-enzyme treatment triggered rapid carrier disassembly, boosting intracellular drug release and lysosome escape in LLC cells. In vitro data showed B/T-PTX-Lip strongly inhibited LLC proliferation, migration and invasion while promoting apoptosis. It raised cellular reactive oxygen species, induced immunogenic cell death and reduced PD-L1 expression. In vivo fluorescence imaging revealed robust tumor aggregation in subcutaneous and lung metastasis mouse models. Animal treatment tests proved potent suppression on primary tumors and pulmonary metastasis, with good biosafety. This dual-enzyme responsive smart liposome offers an effective, low-toxic targeted chemoimmunotherapy strategy for lung cancer, showing promising clinical translational value.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, 116600, China; Shenyang Key Laboratory of Chinese Medicine targeted Delivery Key laboratory, Shenyang, 110148, China.
- College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, 116600, China; Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
- College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, 116600, China; School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
- College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, 116600, China.
- Department of Cardiovasology 3, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, 110148, China. Electronic address: 756175378@qq.com.
- Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, 110148, China. Electronic address: zangningzi@126.com.
Zitieren
APA
Kong, L., Zang, J., Wang, J. H., Liu, M., Gao, Y. F., Guo, R. B., Liu, Y., Zheng, Y., Pang, L. L., Zang, N. Z., & Li, X. T. (2026). Breaking the barrier: MMP2/HAase dual-triggered liposomal nanoplatform for enhanced tumor penetration and immunogenic cell death. International Immunopharmacology, 191, 117601. https://doi.org/10.1016/j.intimp.2026.117601
Vancouver
Kong L, Zang J, Wang JH, Liu M, Gao YF, Guo RB, et al. Breaking the barrier: MMP2/HAase dual-triggered liposomal nanoplatform for enhanced tumor penetration and immunogenic cell death. International Immunopharmacology. 2026;191:117601. doi:10.1016/j.intimp.2026.117601
BibTeX
@article{Kong2026,
author = {Kong, Liang and Zang, Juan and Wang, Jia-Hua and Liu, Mo and Gao, Yi-Fei and Guo, Rui-Bo and Liu, Yang and Zheng, Ying and Pang, Lin-Lin and Zang, Ning-Zi and Li, Xue-Tao},
title = {Breaking the barrier: MMP2/HAase dual-triggered liposomal nanoplatform for enhanced tumor penetration and immunogenic cell death},
journal = {International Immunopharmacology},
year = {2026},
volume = {191},
pages = {117601},
doi = {10.1016/j.intimp.2026.117601}
}
EUVIMED